{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-095195","form_type":"8-K","ticker":"CVKD","cik":"0001937993","company_name":"Cadrenal Therapeutics, Inc.","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:10.386252+00:00","generated_at":"2026-05-30T03:56:51.262917+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cadrenal Therapeutics Q3 2024 cash $11.3M, raises $9.8M from ATM and warrants","bullets":["Q3 2024 operating expenses $2.5M including $0.3M non-cash; cash used in operations $2.2M.","Raised $5.1M via ATM and $4.7M from warrant exercises, totaling $9.8M.","FDA discussions advancing on tecarfarin Phase 3 LVAD trial protocol; Abbott collaboration ongoing.","CDMO completed readiness to supply API and clinical trial materials under cGMP.","Joined Anticoagulation Forum Corporate Council to engage 15,000 healthcare professionals."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-095195","json":"https://secwatch.observer/filing/0001213900-24-095195.json","markdown":"https://secwatch.observer/filing/0001213900-24-095195.md","text":"https://secwatch.observer/filing/0001213900-24-095195.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1937993/000121390024095195/0001213900-24-095195-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1937993/000121390024095195/ea0220315-8k_cadrenal.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:56:51.262917+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}